section name header

Indications ⬇

REMS


Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CNS: headache, drowsiness, weakness

CV: ARRHYTHMIAS, hypertension

EENT: conjunctivitis, photophobia

GI: constipation, nausea, anorexia, dry mouth, metallic taste, pancreatitis, polydipsia, vomiting

Derm: pruritus, rash

F and E: hypercalcemia, hyperphosphatemia, hyperthermia, ↑thirst

GU: albuminuria, hypercalcuria, ↓libido, nocturia, polyuria

Metab: ectopic calcification, hypercholesterolemia, hyperthermia

MS: bone pain, muscle pain

Interactions ⬆ ⬇

Drug-drug:

Availability ⬆ ⬇

Route/Dosage ⬆ ⬇

Action ⬆ ⬇

  • Stimulates intestinal absorption of calcium and phosphorus, reabsorption of calcium from bone and renal reabsorption of calcium.
  • Does not require renal activation.
Therapeutic effects:
  • Improved calcium and phosphorus homeostasis in patients with chronic kidney disease.

Classifications ⬆ ⬇

Therapeutic Classification: vitamins

Pharmacologic Classification: vitamin d analogues

Pharmacokinetics ⬆ ⬇

Absorption: Completely absorbed following oral administration.

Distribution: Unknown.

Protein Binding: Extensively protein bound.

Metabolism/Excretion: Following absorption, 50% is rapidly converted by liver to active metabolite (1.25–(OH)2D; 13% renally excreted.

Half-Life: 3 hr.

Canadian Brand Names ⬆ ⬇

One-Alpha

Time/Action Profile ⬆ ⬇

(levels of active metabolite)

ROUTEONSET‡PEAKDURATION‡
PO6 hr12 hrfew days–1 wk
IVunknown4 hrfew days–1 wk

‡Effect on intestinal calcium absorption, bone pain and muscle weakness improve within 2 wk–3 mo.

‡Effect on serum calcium levels following discontinuation.

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆

AL-fa-KAL-si-dol